AOA Dx, a biotech company developing a new frontier in early-stage cancer detection through its work in glycolipids, is proud to announce the company’s first published peer reviewed clinical study.
The manuscript titled “GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer” has been accepted to the prestigious journal Frontiers in Oncology.
“The ability to detect all types of ovarian cancer using non-invasive methods, and especially with detection at early stages, could enable early intervention, improve outcomes, and increase patient survival” says Professor Saragovi, Chief Scientific Officer at AOA Dx.
AOA Dx’s revolutionary tumor marker ganglioside technology is paving the way for life-saving early cancer detection.The company recently began their first prospective clinical study, OVERT, a multi-center national trial that is the first of its kind in a symptomatic U.S. population. AOA Dx is working with world renowned clinicians and healthcare institutions across the US to bring to market the first non-invasive liquid biopsy test for the early detection of ovarian cancer in symptomatic women.
In their first peer reviewed published manuscript, “GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer”, the researchers investigated the diagnostic utility of GD2 and GD3 for diagnosis of all subtypes and stages of ovarian cancer.
Ovarian cancer is the deadliest gynecological cancer, often diagnosed at advanced stages. A fast and accurate diagnostic method for early-stage ovarian cancer is needed to improve survival outcomes. The tumor marker gangliosides, GD2 and GD3, exhibit properties that make them ideal potential diagnostic biomarkers but they have never before been quantified in ovarian cancer.
The retrospective study evaluated GD2 and GD3 expression in biobanked tissue and serum samples from patients with invasive epithelial ovarian cancer, healthy donors, non-malignant gynecological conditions, and other cancers. GD2 and GD3 levels were evaluated in tissue samples by immunohistochemistry (n=299), and in two cohorts of serum samples by quantitative ELISA. A Discovery Cohort (n=379) showed feasibility of a GD2 and GD3 quantitative ELISA for diagnosing ovarian cancer, and a subsequent Model Cohort (n=200) was used to train and cross-validate a diagnostic model.
GD2 and GD3 were expressed in tissues of all ovarian cancer subtypes and FIGO stages but not in surrounding healthy tissue or other controls. In serum, GD2 and GD3 were elevated in patients with ovarian cancer. A diagnostic model was superior to the standard of care (CA125) in diagnosing Ovarian Cancer as well as early-stage (I/II) Ovarian Cancer.
The study concludes that GD2 and GD3 expression was associated with high rates of selectivity and specificity for early and late stage ovarian cancer. A diagnostic model combining GD2 and GD3 quantification in serum had diagnostic power for all subtypes and all stages of ovarian cancer, including early-stage.
AOA Dx’s work leverages tumor marker ganglioside technology to develop a liquid biopsy test to accurately detect ovarian cancer in symptomatic women, addressing the urgent and unmet need for better early-stage detection.
About AOA Dx Inc.
AOA Dx is pioneering the field of Glycolipids, a new frontier in diagnostics. The proprietary biomarker technology in glycolipids detects early-stage cancer in blood by quantifying circulating gangliosides across multiple cancers and utilizing data science and AI to develop highly accurate diagnostic tests. AOA Dx is focused on women’s health with our first platform product detecting early-stage ovarian cancer, the deadliest gynecological cancer.